세계의 재택 주입 요법 시장 예측(-2030년) : 제품, 투여 경로, 용도, 최종사용자 및 지역별 분석

According to Stratistics MRC, the Global Home Infusion Therapy Market is accounted for $36.85 billion in 2023 and is expected to reach $71.81 billion by 2030 growing at a CAGR of 10% during the forecast period. Home infusion therapy involves giving a patient intravenously or subcutaneously administered medications or biological while they are at home. Moreover, the drug, equipment, and supplies are required to perform a home infusion. Similarly, nursing services are required to instruct and educate the patient and caregivers on how to safely administer infusion drugs at home. Home infusion frequently involves a significant contribution from visiting nurses. Typically, nurses teach patients or caregivers how to self-administer medications, inform them of potential side effects and therapy objectives, and make regular visits to check on the infusion site and change dressings.

According to the American Society of Clinical Oncology (ASCO), home infusion therapy may occasionally provide dangers that necessitate rapid medical attention. In these incredibly rare circumstances, the dangers connected with not having access to biological therapy may exceed the elevated risk of a home infusion.

Market Dynamics:

Driver:

Increasing chronic conditions and an aging population

A significant market driver for home infusion therapy is the rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases. A need for long-term treatments arises as the world population ages and the prevalence of chronic diseases increases. A practical treatment for controlling these conditions that also improves the comfort and quality of life of the patient is home infusion therapy. Additionally, the benefits of administering complex treatments at home are understood by both patients and healthcare professionals, which have caused this market to grow.

Restraint:

Safety issues and regulatory compliance

Home infusion therapy market expansion may be hampered by strict regulatory requirements and safety concerns. Maintaining patient safety requires ensuring compliance with legal requirements for tools, medication handling, and infection control. Furthermore, adverse events that result from not adhering to these standards can affect patient confidence and trust in home-based treatments. To lessen this restriction, it is crucial to implement strong safety measures while maintaining a balance between patient autonomy and governmental oversight.

Opportunity:

Modernization of remote monitoring and telehealth

The market for home infusion therapy has a sizable opportunity due to the integration of telehealth platforms and remote monitoring technology. These innovations allow for remote, real-time monitoring of patient vital signs, treatment development, and adverse reactions. Moreover, the ability to monitor patients remotely improves safety, allows for quick response in the event of complications, and gives medical professionals useful information to modify treatment plans, ultimately leading to better patient outcomes.

Threat:

Data privacy and security issues

Home infusion therapy is becoming more and more dependent on technology and digital platforms, which raises questions about data security and patient privacy. Cybersecurity risks can affect the gathering, storing, and transmission of sensitive patient health information. However, data security issues can jeopardize patient confidentiality, erode public confidence in healthcare providers, and result in legal and regulatory repercussions.

COVID-19 Impact:

The market for home infusion therapy was significantly impacted by the COVID-19 pandemic. Although the initial hiccups in healthcare and supply chains temporarily slowed down service delivery, the pandemic ultimately accelerated the adoption of home-based care due to concerns about hospital-acquired infections. Moreover, telehealth tools have become essential for enabling remote monitoring and consultations. The crisis highlighted the value of home infusion therapy as a secure substitute, triggering technological advancements, regulatory changes, and healthcare collaborations that ultimately reshaped the market's landscape and sparked additional innovation in patient-centered care delivery.

The infusion pumps segment is expected to be the largest during the forecast period

During the forecasted period, the infusion pumps segment was responsible for the largest revenue share. By providing patients with precise and controlled medication and fluid administration in their own homes, the infusion pump segment plays a crucial role. These cutting-edge medical technology tools guarantee precise dosing, monitoring, and therapy customization, improving patient safety, treatment effectiveness, and general convenience. Moreover, the infusion pump market targets both acute and chronic medical conditions, allowing healthcare professionals to confidently administer therapies while empowering patients to take an active role in their recovery processes.

The specialty pharmaceuticals segment is expected to have the highest CAGR during the forecast period

The segment for specialty pharmaceuticals will have the highest CAGR during the forecast period. This growth can be attributed to the rise in demand for specialty drugs and biologics that need to be administered with accuracy, given to each patient individually, and continuously monitored. The targeted therapies provided by this segment benefit patients with chronic and complex conditions, such as autoimmune disorders, rare diseases, and cancer. Furthermore, due to advances in pharmaceutical research and the potential for home-based administration, there is a huge growth for the market expansion.

Region with largest share:

The North American region holds the largest market share for home infusion therapy. The region's established healthcare infrastructure, technological advancements, and rising popularity of home-based care options can all be credited with this dominance. Particularly in the United States and Canada, the demand for home infusion therapy has increased as a result of the aging population, the increasing prevalence of chronic diseases, and the focus on patient-centered care. Additionally, the development of home infusion services in North America has also been aided by favourable governmental regulations, payment schemes, and the incorporation of telehealth.

Region with highest CAGR:

The Asia-Pacific region has the market for home infusion therapy with the highest CAGR during the forecast period. This remarkable expansion is attributed to a number of variables, including the rising awareness of home-based healthcare options, the rise in chronic disease prevalence, and the development of the healthcare infrastructure in nations like China, India, and Japan. However, the adoption of home infusion therapy as a practical and efficient treatment option is being fueled by the area's dense population and advancements in telehealth technology.

Key players in the market:

Some of the key players in Home Infusion Therapy market include: Option Care Health Inc., Nipro Corporation, Baxter International, Inc., JMS Co., Ltd., Micrel Medical Devices SA, PharMerica, B. Braun Melsungen AG, Terumo Corporation, CVS/Coram , Dickinson and Company, Eitan Medical Ltd , McKesson Medical-Surgical Inc., Smiths Medical. , Caesarea Medical Electronics, BriovaRx/Diplomat (UnitedHealth Optum) , ICU Medical, Inc., CareFusion Corporation, McLaren Health Care, Becton Dickinson and Company and CU Medical, Inc.

Key Developments:

In June 2023, Baxter International, an American healthcare company, introduced Progressa+ Next Gen ICU bed for addressing critical needs of patients at their homes. This technology makes it easier for nurses to take care of patients, while supporting therapy at home.

In May 2023, Option Care Health, a healthcare service provider, created an independent platform for home care services in collaboration with Amedisys Inc., a leading provider of home health services. This platform comprises pharmacists, dieticians, therapists, social workers, and others for providing high quality healthcare services at home.

In April 2023, CareFusion, currently owned by Becton Dickinson, an American medical technology company, launched an advanced ultrasound technology to provide clinicians with optimal IV insertions. More than 90% hospitalized patients receive the IV therapy, thus contributing towards the market growth of home infusion therapy.

Products Covered:

• Infusion Pumps
• Intravenous Sets
• IV Cannulas
• Needleless Connectors
• Disposable Elastomeric Pumps
• Insulin Pumps
• PCA Pumps
• Electronic Ambulatory Pumps
• Other Products

Routes of Administration Covered:

• Intramuscular
• Subcutaneously
• Epidural
• Other Routes of Administration

Applications Covered:

• Anti-Infective
• Endocrinology
• Hydration Therapy
• Chemotherapy
• Enteral Nutrition
• Parenteral Nutrition
• Specialty Pharmaceuticals
• Inotropic Therapy
• Pain Management
• HIV Therapies
• Post-transplant Therapies
• Antibiotic Administration
• Haemophilia Therapies
• Other Applications

End Users Covered:

• Patients
• Nurse
• Hospitals
• Home Care Settings
• Long-Term Care Center
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Home Infusion Therapy Market, By Product

• 5.1 Introduction
• 5.2 Infusion Pumps
  • 5.2.1 Elastomeric
  • 5.2.2 Electromechanical
  • 5.2.3 Gravity
• 5.3 Intravenous Sets
• 5.4 IV Cannulas
• 5.5 Needleless Connectors
• 5.6 Disposable Elastomeric Pumps
• 5.7 Insulin Pumps
• 5.8 PCA Pumps
• 5.9 Electronic Ambulatory Pumps
• 5.10 Other Products

6 Global Home Infusion Therapy Market, By Route of Administration

• 6.1 Introduction
• 6.2 Intramuscular
• 6.3 Subcutaneously
• 6.4 Epidural
• 6.5 Other Routes of Administration

7 Global Home Infusion Therapy Market, By Application

• 7.1 Introduction
• 7.2 Anti-Infective
• 7.3 Endocrinology
  • 7.3.1 Diabetes
• 7.4 Hydration Therapy
  • 7.4.1 Athletes
• 7.5 Chemotherapy
• 7.6 Enteral Nutrition
• 7.7 Parenteral Nutrition
• 7.8 Specialty Pharmaceuticals
• 7.9 Inotropic Therapy
• 7.10 Pain Management
• 7.11 HIV Therapies
• 7.12 Post-transplant Therapies
• 7.13 Antibiotic Administration
• 7.14 Haemophilia Therapies
• 7.15 Other Applications

8 Global Home Infusion Therapy Market, By End User

• 8.1 Introduction
• 8.2 Patients
• 8.3 Nurse
• 8.4 Hospitals
• 8.5 Home Care Settings
• 8.6 Long-Term Care Center
• 8.7 Other End Users

9 Global Home Infusion Therapy Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Option Care Health Inc.
• 11.2 Nipro Corporation
• 11.3 Baxter International, Inc.
• 11.4 JMS Co., Ltd.
• 11.5 Micrel Medical Devices SA
• 11.6 PharMerica
• 11.7 B. Braun Melsungen AG
• 11.8 Terumo Corporation
• 11.9 CVS/Coram
• 11.10 Dickinson and Company
• 11.11 Eitan Medical Ltd
• 11.12 McKesson Medical-Surgical Inc.
• 11.13 Smiths Medical.
• 11.14 Caesarea Medical Electronics
• 11.15 BriovaRx/Diplomat (UnitedHealth Optum)
• 11.16 ICU Medical, Inc.
• 11.17 CareFusion Corporation
• 11.18 McLaren Health Care
• 11.19 Becton Dickinson and Company
• 11.20 CU Medical, Inc.